Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30727480 | 0.89 | PDE5A (0.57) | PDE5APDE10A | |
| SCHEMBL1679808 | 0.89 | PDE5A (0.57) | PDE5APDE10A | |
| SCHEMBL16816047 | 0.88 | PDE5A (0.66) | PDE5A | |
| SCHEMBL19158808 | 0.87 | PDE5A (0.43) | PDE5A | |
| SCHEMBL16816613 | 0.86 | PDE5A (0.66) | PDE5A | |
| SCHEMBL16346217 | 0.86 | PDE5A (0.57) | PDE5APDE10A | |
| SCHEMBL17013476 | 0.85 | AGTR1 (0.39) | PDE5A | |
| SCHEMBL16348033 | 0.83 | PDE5A (0.44) | PDE5A | |
| SCHEMBL4974720 | 0.82 | PDE5A (0.54) | PDE5APDE10A | |
| SCHEMBL31189121 | 0.82 | PDE5A (0.54) | PDE5APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2980087-B1 | PRODRUGS OF BICYCLIC SUBSTITUTED PYRIMIDINE TYPE PDE-5 INHIBITORS | XUANZHU PHARMA CO LTD (CN) | 2018-06-06 | — | — | EP | disclosed |
| CN-104487434-B | Double cyclosubstituted pyrimidines | 山东轩竹医药科技有限公司 | 2018-05-22 | — | — | CN | disclosed |
| CN-105102447-B | The prodrug of double cyclosubstituted inhibitor of miazines PDE 5 | 山东轩竹医药科技有限公司 | 2017-08-25 | — | — | CN | disclosed |
| EP-2886540-B1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | XUANZHU PHARMA CO LTD (CN) | 2017-07-26 | — | — | EP | disclosed |
| EP-2886540-B1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | XUANZHU PHARMA CO LTD (CN) | 2017-07-26 | — | — | EP | disclosed |
| US-9359371-B2 | Bicyclic substituted pyrimidine compounds | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9359371-B2 | Bicyclic substituted pyrimidine compounds | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| EP-2980087-A1 | BICYCLIC SUBSTITUTED PYRIMIDINE PDE-5 INHIBITOR PRODRUG | Xuanzhu Pharma Co., Ltd. (CN) | 2016-02-03 | — | — | EP | disclosed |
| CN-105102447-A | Bicyclic substituted pyrimidine PDE-5 inhibitor prodrug | XUANZHU PHARMA CO LTD | 2015-11-25 | — | — | CN | disclosed |
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2015-08-20 | — | — | US | disclosed |
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2015-08-20 | — | — | US | disclosed |
| EP-2886540-A1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-24 | — | — | EP | disclosed |
| EP-2886540-A1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-24 | — | — | EP | disclosed |
| CN-104487434-A | Bicyclic substituted pyrimidine compounds | XUANZHU PHARMA CO LTD | 2015-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | DPYD, UMPS, TYMP | PDE5A 81/4885PDE10A 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.